Mariano Barbacid

Mariano Barbacid got his PhD in Madrid’s Universidad Complutense (1974) and trained as a postdoctoral fellow at the US National Cancer Institute (1974-78). In 1978 he started his own research group to study the molecular events responsible for the development of human tumours. His work led in the spring of 1982, to the isolation of the first human oncogene and the identification of the first mutation associated with the development of human cancer. These findings, also made independently by two other groups, have been seminal to establish the molecular bases of human cancer. In 1988, he joined Bristol Myers-Squibb where he became Vice President, Oncology Drug Discovery. In this position, he pioneered the development of what we know now as targeted therapies. In 1998, he returned to Madrid to create and direct the Spanish National Cancer Research Center (CNIO). In 2011 he stepped down as Director to concentrate on his own research currently centred on the identification and validation of novel therapeutic strategies against K-RAS mutamt lung and pancreatic tumours. In 2012, he was inducted to the US National Academy of Sciences and in 2014, elected Fellow of the Academy of the American Association for Cancer Research. He holds Honorary Degrees (Doctor Honoris Causa) from the Universidad Internacional Menendez y Pelayo (1995), University of Cantabria (2011) and University of Barcelona (2014). His work has been recognised by several domestic and international awards including the Steiner Prize (Bern, 1988), Ipsen Prize (Paris, 1994), Brupbaher Cancer Research Prize (Zurich, 2005), the Medal of Honour of the International Agency for Cancer Research (Lyon, 2007) and the Burkitt Medal (Dublin, 2017). In 2011, he received an Endowed Chair from the AXA Research Fund (Paris). He is one of the few European scientists to receive two Advanced Grants from the European Research Council (2009 and 2015) since their inception in 2008. To date, Dr Barbacid has authored 310 publications, including 231 original research articles in journals with impact factor. Currently, Dr Barbacid’s Hirsch “h” factor is 114 (Google Scholar) and 107 (Web of Science)